Mechanisms leading to the development of hormone-resistant prostate cancer

被引:57
作者
Kasper, Susan [1 ]
Cookson, Michael S. [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.ucl.2005.12.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Advanced and metastatic prostate cancers remain potentially lethal tumors. Although androgen deprivation therapy remains the most effective treatment, patients who progress to androgen independence die of their disease. This article focuses on the mechanisms by which hormone resistance develops, including the reactivation of androgen receptor during androgen deprivation therapy, the role of cancer stem cells, and the emergence of epithelial-mesenchymal transition cells, which have increased metastatic potential. It is through an enhanced understanding of these mechanisms that new therapies can be developed to combat this disease.
引用
收藏
页码:201 / +
页数:11
相关论文
共 78 条
[1]
[Anonymous], 1997, Br J Urol, V79, P235
[2]
Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO
[3]
2-L
[4]
Neurogenic origin of human prostate endocrine cells [J].
Aumüller, G ;
Leonhardt, M ;
Janssen, M ;
Konrad, L ;
Bjartell, A ;
Abrahamsson, PA .
UROLOGY, 1999, 53 (05) :1041-1048
[5]
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[6]
Buchanan G, 2001, CLIN CANCER RES, V7, P1273
[7]
BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO
[8]
2-C
[9]
Plasma insulin-like growth factor I and prostate cancer risk: A prospective study [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, E ;
Gann, PH ;
Ma, J ;
Wilkinson, P ;
Hennekens, CH ;
Pollak, M .
SCIENCE, 1998, 279 (5350) :563-566
[10]
Society of urologic oncology position statement: Redefining the management of hormone-refractory prostate carcinoma [J].
Chang, SS ;
Benson, MC ;
Campbell, SC ;
Crook, J ;
Dreicer, R ;
Evans, CP ;
Hall, MC ;
Higano, C ;
Kelly, WK ;
Sartor, O ;
Smith, JA .
CANCER, 2005, 103 (01) :11-21